Shanghai, China – February 11, 2026. The Toumai® laparoscopic surgical robot has surpassed 200 units in global commercial orders, covering nearly 50 countries and regions, with close to 130 systems already installed commercially.
This milestone represents continued global adoption across diverse healthcare systems and surgical specialties. From exceeding 100 global orders in October 2025 to surpassing 200 in February 2026, Toumai® has doubled its order volume within just a few months, maintaining a clear trajectory of exponential growth.
Among the nearly 50 countries and regions where Toumai® has secured orders, 12 markets have placed more than five orders each, signaling progression from initial deployment to broader institutional integration. Growth has been particularly notable in emerging markets, including India (14 cumulative orders) and Brazil (over 10 orders), while developed markets such as Spain and Australia continue to expand adoption.
Clinically, Toumai® has supported a broad range of surgical procedures across urology, general surgery, thoracic surgery, gynecology, and head and neck surgery. More than 96% of cumulative cases have involved Level III and Level IV complex procedures. Nearly 800 remote robotic surgeries have been performed across more than 20 countries, maintaining a 100% procedural success rate.
Following installation, dozens of hospitals worldwide have surpassed 100 cases per center, reflecting routine clinical utilization. The system continues to demonstrate stable performance and consistent integration into high-complexity surgical workflows.
With 200 global commercial orders and expanding multi-regional deployment, Toumai® continues to strengthen its international presence in robotic-assisted surgery.